US 2017/0107261 A1 · Chemically Activated Nanocapsid Functionalized for Cancer Targeting

Abstract

Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids.

Claims46

Dependent claims

A modified capsid protein comprising a portion of hepatitis E virus (HEV) open Reading Frame 2 (ORF2) protein that is able to form an acid and proteolytically stable HEV virus like particle (VLP), wherein:

the portion of HEV ORF2 comprises a P-domain of the HEV ORF2 protein;
the P-domain comprises at least one surface variable loop and a C-terminus;
the P-domain comprises a cysteine in the at least one surface variable loop or at the C-terminus;
and
the HEV ORF2 portion retains its ability to form an acid and proteolytically stable HEV VLP when the surface variable loop or C-terminal cysteine is chemically derivatized.

2 more elements

Dependencies are inferred from the claim text.

Chemically Activated Nanocapsid Functionalized for Cancer Targeting

Life of this patent

Chemically Activated Nanocapsid Functionalized for Cancer Targeting

Life of this patent

Abstract

Claims46